首页> 外文期刊>Neuromolecular medicine >Low-Density Lipoprotein Receptor-Related Protein-1 (LRP1) C4408R Mutant Promotes Amyloid Precursor Protein (APP) alpha-Cleavage in Vitro
【24h】

Low-Density Lipoprotein Receptor-Related Protein-1 (LRP1) C4408R Mutant Promotes Amyloid Precursor Protein (APP) alpha-Cleavage in Vitro

机译:低密度脂蛋白受体相关蛋白-1(LRP1)C4408R突变体在体外促进淀粉样蛋白前体蛋白(APP)α-切割

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Previous studies have demonstrated that the low-density lipoprotein receptor-related protein-1 (LRP1) plays conflicting roles in Alzheimer's disease (AD) pathogenesis, clearing beta-amyloid (A beta) from the brain while also enhancing APP endocytosis and resultant amyloidogenic processing. We have recently discovered that co-expression of mutant LRP1 C-terminal domain (LRP1-CT C4408R) with Swedish mutant amyloid precursor protein (APPswe) in Chinese hamster ovary (CHO) cells decreases A beta production, while also increasing sAPP alpha and APP alpha-C-terminal fragment (alpha-CTF), compared with CHO cells expressing APPswe alone. Surprisingly, the location of this mutation on LRP1 corresponded with the alpha-secretase cleavage site of APP. Further experimentation confirmed that in CHO cells expressing APPswe or wild-type APP (APPwt), co-expression of LRP1-CT C4408R decreases A beta and increases sAPP alpha and alpha-CTF compared with co-expression of wild-type LRP1-CT. In addition, LRP1-CT C4408R enhanced the unglycosylated form of LRP1-CT and reduced APP endocytosis as determined by flow cytometry. This finding identifies a point mutation in LRP1 which slows LRP1-CT-mediated APP endocytosis and amyloidogenic processing, while enhancing APP alpha-secretase cleavage, thus demonstrating a potential novel target for slowing AD pathogenesis.
机译:以前的研究表明,低密度脂蛋白受体相关蛋白-1(LRP1)在阿尔茨海默病(AD)发病机制中起矛盾的作用,从大脑中清除β-淀粉样蛋白(Aβ),同时增强App内吞作用和所得淀粉样蛋白加工。我们最近发现突变体LRP1 C-末端结构域(LRP1-CT C4408R)与瑞典突变蛋白前体蛋白(Appswe)的突变体LRP1 C-末端结构蛋白(Appswe)降低了β制作,同时也增加了SAPPα和应用程序与单独表达Appswe的CHO细胞相比,α-C末端片段(α-CTF)。令人惊讶的是,这种突变对LRP1的位置对应于APP的α-分泌酶切割位点。进一步的实验证实,在表达Appswe或野生型APP(APPWT)的CHO细胞中,与野生型LRP1-CT的共表达相比,LRP1-CT C4408R的共表达降低了β并增加了SAPPα和α-CTF。此外,通过流式细胞术测定,LRP1-CT C4408R增强了LRP1-CT的不凝胶化形式的LRP1-CT和减少的应用内吞作用。该发现鉴定了LRP1中的点突变,其减缓了LRP1-CT介导的应用内吞作用和淀粉样蛋白加工,同时增强了APPα-分泌酶切割,从而证明了用于减缓AD发病机制的潜在新靶点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号